Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA3 | P07451 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA6 | P23280 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA7 | P43166 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.30 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2601752 | 0.82 | — | — | |
| SCHEMBL27705607 | 0.75 | CA12 (0.52) | TDP1CA12CA1CA2CA3 | |
| SCHEMBL11214086 | 0.75 | — | — | |
| SCHEMBL3859285 | 0.74 | DNM1 (0.32) | DNM1TSHR | |
| SCHEMBL7766848 | 0.72 | — | — | |
| SCHEMBL5268953 | 0.72 | DNM1 (0.38) | FDPSDNM1TSHR | |
| SCHEMBL10406162 | 0.72 | ODC1 (0.38) | NFKB1FDPSPDE3ATDP1LMNA | |
| SCHEMBL10805587 | 0.72 | CHRM2 (0.32) | CHRM2 | |
| SCHEMBL7755142 | 0.70 | CHRM2 (0.46) | CHRM2TDP1 | |
| SCHEMBL679280 | 0.70 | TSHR (0.42) | FDPSDNM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403856-B1 | METHYLENEDIOXYBENZO [I]PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | UNIV RUTGERS (US) | 2012-12-19 | — | — | EP | claimed |
| WO-2023116761-A1 | PYRIMIDINE HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE | 英矽智能科技知识产权有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-10179789-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170355706-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355706-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-12-14 | — | — | US | disclosed |
| US-9562051-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562051-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2403856-B1 | METHYLENEDIOXYBENZO [I]PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | UNIV RUTGERS (US) | 2012-12-19 | — | — | EP | disclosed |
| CN-101879297-B | Prostate recovery capsules of Chinese medicinal compound preparation, preparation process and application thereof | NANCHANG MALE HOSPITAL | 2012-05-09 | — | — | CN | disclosed |
| US-20120101117-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-04-26 | — | — | US | disclosed |
| US-20120101117-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-04-26 | — | — | US | disclosed |
| CN-101879297-A | Prostate recovery capsules of Chinese medicinal compound preparation, preparation process and application thereof | NANCHANG CITY MALE HOSPITAL | 2010-11-10 | — | — | CN | disclosed |
| WO-2010102219-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179789-B2 | Methylenedioxybenzo [I] phenanthridine derivatives used to treat cancer | TOP2B, TOP1, TOP2A | CHRM2 4220/4885NFKB1 626/4885FDPS 1027/4885 |
| US-20170355706-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | TOP2B, TOP1, TOP2A | CHRM2 4220/4885NFKB1 626/4885FDPS 1027/4885 |
| US-20120101117-A1 | METHYLENEDIOXYBENZO [I] PHENANTHRIDINE DERIVATIVES USED TO TREAT CANCER | TOP2B, TOP1, TOP2A | CHRM2 4220/4885NFKB1 626/4885FDPS 1027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.